Over 2021 the group has made significant contributions towards understanding gene silencing by promoter methylation in colorectal cancer, which significantly contributes to the oncogenic process by restricting the expression of tumor suppressor genes such as ZBTB18. We have deepened our knowledge on the role of Myosin Vb and RhoA in colorectal and gastric cancer, respectively. Mutations in MYO5B gene result in a loss of protein function in enterocytes, leading to microvillus inclusion rare disease. We have engineered a conditional and inducible mouse model recapitulating the human syndrome, which is currently being used for testing the efficacy of novel therapies. The laboratory is also involved in the development of cancer therapies using nanosystems. We are actively exploring the value of nanoparticles functionalized with CXCR4 inhibitory peptides as theranostic agents, and the use of CD300f-based cell-penetrating peptides to design more effective therapeutic nanoconjugates.

Group Leader
Diego Arango del Corro

Researchers
Águeda Martínez Barriocanal

PhD Students
Estefanía Anguita Espinosa, Li Jing, Bruno Brotons Morales

Lab Technicians
Mariona Dalmau Längst

5

PUBLICATIONS

29

IMPACT FACTOR

5.74

AVERAGE IMPACT FACTOR

SELECTED ARTICLES

Giralt I, Gallo-Oller G, Navarro N, Zarzosa P, Pons G, Magdaleno A, Segura MF, Sábado C, Hladun R, Arango D, Sánchez de Toledo J, Moreno L, Gallego S, Roma J
Dickkopf-1 Inhibition Reactivates Wnt/β-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo
Int J Mol Sci. 2021 Nov 29;22(23):12921
DOI: 10.3390/ijms222312921
IF: 5.542

Bazzocco S, Dopeso H, Martínez-Barriocanal Á, Anguita E, Nieto R, Li J, García-Vidal E, Maggio V, Rodrigues P, de Marcondes PG, Schwartz S Jr, Aaltonen LA, Sánchez A, Mariadason JM, Arango D
Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis
Clin Epigenetics. 2021 Apr 23;13(1):88
DOI: 10.1186/s13148-021-01070-0
IF: 6.551

Andrade F, Rafael D, Vilar-Hernández M, Montero S, Martínez-Trucharte F, Seras-Franzoso J, Díaz-Riascos ZV, Boullosa A, García-Aranda N, Cámara-Sánchez P, Arango D, Nestor M, Abasolo I, Sarmento B, Schwartz S Jr
Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo
J Control Release. 2021 Mar 10;331:198-212
DOI: 10.1016/j.jconrel.2021.01.022
IF: 9.776

Nueva estrategia terapéutica para el cáncer gástrico basada en la modulación de la señalización de RHOA
Principal Investigator: Diego Arango del Corro
Agency: Instituto de Salud Carlos III
Funding: 236,857€
Period: 2020-2022

Desarrollo de nanosistemas de marcaje de CXCR4 mediante radiosondas para la imagen molecular de células tumorales y del microambiente tumoral
Principal Investigator: Diego Arango del Corro
Agency: Euronanomed3-Instituto de Salud Carlos III
Funding: 99,946€
Period: 2020-2022

RHOA signaling in gastric cancer: friend or foe?
Principal Investigator: Diego Arango del Corro
Agency: Asociación Española Contra el Cáncer
Funding: 1,015,000€
Period: 2015-2022

Identificación de nuevos biomarcadores de respuesta a los compuestos regorafenib y TAS-102 en pacientes con cáncer colorrectal
Principal Investigator: Diego Arango del Corro
Agency: Instituto de Salud Carlos III
Funding: 122,815€
Period: 2017-2021

Cell-penetrating peptides
Priority Number: EP20382968
Priority Date: 10/11/2020
Applicants: Fundació Hospital Universitari Vall d’Hebron - Institut de Recerca (VHIR), Consorcio Centro de Investigación Biomédica en Red (CIBER)

Oncology

Research Areas